Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for ripretinib

  1. Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)

    Evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after 3 or more treatments.

    Technology appraisal guidance
    Published
    3 May 2023
    View recommendations

    Sections for TA881

  2. Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881) [ID6496]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation